Please login to the form below

Not currently logged in
Email:
Password:

Sanofi appoints Pfizer's Rita Balice-Gordon to lead neurobiology research

She will be based at the firm's Framingham, Massachusetts R&D site

Sanofi Rita Balice-GordonSanofi has appointed Rita Balice-Gordon as head of its neurobiology research therapeutic area.

She joins the French pharma firm from Pfizer, where she served as head of circuits, neurotransmitters and signaling in the its neuroscience and pain research unit.

During her time there she led a global team and was responsible for the company's worldwide research and development postdoctoral programme.

Prior to her time at Pfizer Balice-Gordon was professor of neuroscience and chair of the neuroscience graduate group in the Perelman School of Medicine at the University of Pennsylvania, where she currently holds an adjunct appointment.

In her new role at Sanofi Balice-Gordon will based at the firm's Framingham, Massachusetts R&D site and lead research efforts associated with Sanofi's early portfolio in neurobiology, including neurodegeneration, neuroinflammation and central nervous system inherited diseases.

18th May 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics